Epoxomicin | 2190

Originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity, Epoxomicin is a potent, cell-permeable, selective and irreversible proteasome inhibitor. More potent inhibitor of the chymotrypsin-like activity of the proteasome than Lactacystin (Cat. No. 1709-100). Blocks also trypsin-like and PGPH activities of the proteasome.

Epoxomicin is a potent, cell-permeable, selective and irreversible proteasome inhibitor. More potent inhibitor of the chymotrypsin-like activity of the proteasome than Lactacystin (Cat. No. 1709-100). Blocks also trypsin-like and PGPH activities of the proteasome.

2190 | Epoxomicin DataSheet

Alternate Name/Synonyms: N-​acetyl-​N-​methyl-​L-​isoleucyl-​L-​isoleucyl-​N-​[(1S)-​3-​methyl-​ 1-​[[(2R)-​2-​methyloxiranyl]carbonyl]butyl]-​L-​threoninamide; BU-4061T

Appearance: White solid

Formulation: N/A

CAS Number: 134381-21-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₈H₅₀N₄O₇

Molecular Weight: 554.7

Cell-Permeable?: Yes

Purity: ≥95% by HPLC

Solubilities: DMSO (~ 10 mg/ml)

Handling: Protect from air and moisture

Country of Origin: USA

Tag Line: A potent proteasome inhibitor

MDL Number: MFCD03791061

PubChem CID: 11226684

SMILES: CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(C)C)C(=O)C1(CO1)C)NC(=O)C(C(C)CC)N(C)C(=O)C

InChi: InChI=1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1

InChi Key: DOGIDQKFVLKMLQ-JTHVHQAWSA-N